T. Guzi

发表

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

E. Lees, T. Fischmann, P. Kirschmeier, 2010, Molecular Cancer Therapeutics.

linical Development aciclib ( SCH 727965 ) , a Novel and Potent Ther lin-Dependent Kinase Inhibitor

Parry, E. Lees, P. Kirschmeier, 2010 .

CYC-202 Cyclacel.

T. Guzi, 2004, Current opinion in investigational drugs.

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.

E. Lees, T. Fischmann, P. Kirschmeier, 2010, ACS medicinal chemistry letters.

Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: a template-based approach.

T. Fischmann, T. Guzi, K. Paruch, 2013, Bioorganic & medicinal chemistry letters.

1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC

K. Hoeflich, B. Cho, T. Guzi, 2020 .

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.

T. Fischmann, W. Seghezzi, D. Parry, 2011, Bioorganic & medicinal chemistry letters.

Syntheses of 5´-amino-2´,5´-dideoxy-2´,2´-difluorocytidine derivatives as novel anticancer nucleoside analogs

T. Guzi, K. Paruch, M. Dwyer, 2014 .

Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved Tolerability.

T. Fischmann, M. Altman, X. Fradera, 2019, Journal of medicinal chemistry.

Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.

E. Lees, T. Fischmann, W. Seghezzi, 2007, Bioorganic & medicinal chemistry letters.

Phenotypic enhancement of thymidylate synthetase pathway inhibitors following ablation of Neil1 DNA glycosylase/lyase

R. Pierce, F. Shanahan, D. Parry, 2010, Cell cycle.

Analogues of 1-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo-[5,6]-cyclohepta [1,2-b]pyridin-11-yl)piperidine as inhibitors of farnesyl protein transferase.

W. R. Bishop, T. Guzi, A. Nomeir, 1999, Bioorganic & medicinal chemistry.

Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin.

Y. Pommier, T. Guzi, T. Macdonald, 1992, Cancer research.

Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma

Nicolas Stransky, K. Hoeflich, C. Lengauer, 2022, Gastro Hep Advances.

Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.

Brian McKittrick, Yaolin Wang, Emma Lees, 2007, Bioorganic & medicinal chemistry letters.

DNA topoisomerase II inhibition by substituted 1,2,3,4-tetrahydro-β-carboline derivatives

T. Guzi, T. Macdonald, J. Madalengoitia, 1994 .

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.

T. Fischmann, W. Seghezzi, D. Parry, 2011, Bioorganic & medicinal chemistry letters.

A 6-exo-trig radical cyclization approach to the hydrochrysene skeleton

T. Guzi, Xuqing Zhang, L. Pettus, 2002 .

Dilithium Tris(1‐pentynyl)cuprate

T. Guzi, T. Macdonald, 2001 .

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.

S. Ou, C. Lengauer, Wei Hu, 2018, Cancer discovery.

Synthesis of substituted 1H-imidazol-1-ylmethylpiperidines. Facile separation of 1,4- and 1,5-disubstituted imidazoles

T. Guzi, Nilukshi Jayasuriya, D. Rane, 2002 .

Preparation and Diastereoselective Birch Reduction−Alkylation of Chiral 3,4-Dihydro-1(2H)-isoquinolinones. Enantiospecific Syntheses and Opioid Receptor Affinities of Several Hydro-2,3- dimethyl-1H-7,12a-methanobenzo[6,7]cycloocta[1,2-c]pyridine-9-ols

T. Guzi, J. Bidlack, K. Thakkar, 1998 .

The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors.

D. Wyss, W. Seghezzi, F. Shanahan, 2014, Bioorganic & medicinal chemistry.

Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening

W. Seghezzi, F. Shanahan, Ming Liu, 2011, Molecular Cancer Therapeutics.

Phe19 Modification of HDM2-p53 PPI Inhibitors to Alleviate CYP3A4 Metabolism/Mechanism-based Inhibition Liability.

Yaolin Wang, T. Guzi, R. Doll, 2022, Bioorganic & medicinal chemistry letters.

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.

Nicolas Stransky, C. Lengauer, C. Winter, 2015, Cancer discovery.

A precision therapy against cancers driven by KIT/PDGFRA mutations

A. Gardino, N. Lydon, M. Heinrich, 2017, Science Translational Medicine.

Survey of rabies preexposure and postexposure prophylaxis among missionary personnel stationed outside the United States.

J. Childs, T. Guzi, P. Arguin, 2006, Journal of travel medicine.

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.

Yoon-Koo Kang, K. Hoeflich, C. Lengauer, 2019, Cancer discovery.

Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors.

David Parry, T. Fischmann, W. Seghezzi, 2010, Bioorganic & medicinal chemistry letters.

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

Ayşegül Özen, N. Brooijmans, T. Guzi, 2022, Journal of medicinal chemistry.

Structure Overhaul Affords a Potent Purine PI3K delta Inhibitor with Improved Tolerability.

T. Fischmann, X. Fradera, T. Guzi, 2019 .

Structure-guided discovery of cyclin-dependent kinase inhibitors.

Emma Lees, David Parry, Kamil Paruch, 2008, Biopolymers.

Abstract 1262: BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC

S. Kazmirski, Ayşegül Özen, K. Hoeflich, 2021, Experimental and Molecular Therapeutics.

Evaluation of PRKACA as a Therapeutic Target for Fibrolamellar Carcinoma

Nicolas Stransky, K. Hoeflich, C. Lengauer, 2022, bioRxiv.

Abstract 791: BLU-285, the first selective inhibitor of PDGFRα D842V and KIT Exon 17 mutants

A. Gardino, C. Lengauer, T. Guzi, 2015 .

In vitro and in vivo characterization of SCH727965 a novel potent cyclin dependent kinase inhibitor

E. Lees, P. Kirschmeier, Yaolin Wang, 2007 .

First Selective KIT D816V Inhibitor for Patients with Systemic Mastocytosis

A. Gardino, C. Lengauer, T. Guzi, 2014 .

Abstract #2490: Targeting the replication checkpoint with a potent and selective CHK1 inhibitor

R. Pierce, W. Seghezzi, F. Shanahan, 2009 .

A convergent preparation of the CHK1 inhibitor MK-8776 (SCH 900776)

T. Guzi, M. Dwyer, R. Rossman, 2016 .